Abstract:Background: Exenatide is an insulinotropic peptide drug for type 2 diabetes treatment with low risk of hypoglycemia, and is administrated by subcutaneous injection. Oral administration is the most preferred route for lifelong treatment of diabetes, but oral delivery of peptide drug remains a significant challenge due to the absorption obstacles in gastrointestinal tract. We aimed to produce exenatide-loaded nanoparticles containing absorption enhancer, protectant and stabilizer using FDA approved inactive ingredients and easy to scale-up method, and to evaluate their long-term oral therapeutic effect in type 2 diabetes db/db mice. Results: Two types of nanoparticles, named COM NPs and DIS NPs, were fabricated using anti-solvent precipitation method. In COM NPs, the exenatide was complexed with cholic acid and phosphatidylcholine to increase the exenatide loading efficiency. In both nanoparticles, zein acted as the cement and the other ingredients were embedded in zein nanoparticles by hydrophobic interaction. Casein acted as the stabilizer. The nanoparticles had excellent lyophilization, storage and re-dispersion stability. Hypromellose phthalate protected the loaded exenatide from degradation in simulated gastric fluid. Cholic acid promoted the intestinal absorption of the loaded exenatide via bile acid transporters. The exenatide loading efficiencies of COM NPs and DIS NPs were 79.7% and 53.6%, respectively. The exenatide oral pharmacological availability of COM NPs was 18.6% and DIS NPs was 13.1%. COM NPs controlled the blood glucose level of the db/db mice well and the HbA1c concentration significantly decreased to 6.8% during and after 7 weeks of once daily oral administration consecutively. Both DIS NPs and COM NPs oral groups substantially increased the insulin secretion by more than 60% and promoted the β-cell proliferation by more than 120% after the 7-week administration. Conclusions: Both COM NPs and DIS NPs are promising systems for oral delivery of exenatide, and COM NPs are better in blood glucose level control than DIS NPs. Using prolamin to produce multifunctional nanoparticles for oral delivery of peptide drug by hydrophobic interaction is a simple and effective strategy.

Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats.

Application of model-based methods to characterize exenatide-loaded double-walled microspheres: in vivo release, pharmacokinetic/pharmacodynamic model, and in vitro and in vivo correlation.

Pharmacokinetic/pharmacodynamic Studies on Exenatide in Diabetic Rats

Exenatide-loaded PLGA Microspheres with Improved Glycemic Control: in Vitro Bioactivity and in Vivo Pharmacokinetic Profiles after Subcutaneous Administration to SD Rats.

Double Layer Spherical Nanoparticles with Hyaluronic Acid Coating to Enhance Oral Delivery of Exenatide in T2DM Rats.

Preparation, Characterization, and Pharmacodynamics of Exenatide-Loaded Poly(DL-lactic-co-glycolic Acid) Microspheres

A Simple Blood Microdialysis in Freely-Moving Rats for Pharmacokinetic–pharmacodynamic Modeling Study of Shengmai Injection with Simultaneous Determination of Drug Concentrations and Efficacy Levels in Dialysate

Oral Delivery of Exenatide Via Microspheres Prepared by Cross-Linking of Alginate and Hyaluronate.

In Vitro and in Vivo Sustained Release of Exenatide from Vesicular Phospholipid Gels for Type II Diabetes

Preparation and evaluation of lactic acid acylated exenatide and its long-acting preparation

Exenatide-loaded Glucose-Responsive Microspheres for Intelligent Diabetic Therapy

Exenatide Loaded PLGA Microspheres for Long-Acting Antidiabetic Therapy: Preparation, Characterization, Pharmacokinetics and Pharmacodynamics

Development and Validation of A Reverse-Phase High Performance Liquid Chromatography Method for Determination of Exenatide in Poly(Lactic-Co-Glycolic Acid) Microspheres

The Glucose-Lowering Potential of Exenatide Delivered Orally via Goblet Cell- Targeting Nanoparticles

Characterization and Compatibility Studies of Different Rate Retardant Polymer Loaded Microspheres by Solvent Evaporation Technique: In Vitro-In Vivo Study of Vildagliptin as a Model Drug

Effects of Exenatide on Lipid Metabolism of Adipose Tissue in Diabetic Rats

Site-specific Fatty Chain-Modified Exenatide Analogs with Balanced Glucoregulatory Activity and Prolonged in Vivo Activity.

Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice

Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance.

A Novel Peptide with Similar Pharmacology to Exenatide in Rodents As GLP-1 Receptor Agonist

In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.